Practice toolkit
Dermatology Patient Screening & Candidacy Toolkit for Practices
After using this toolkit, your clinical team will systematically identify ideal candidates, document exclusion criteria, and optimize intake workflows for regenerative dermatology therapies.
This practice toolkit provides standardized patient screening criteria and clinical intake workflows for dermatological and aesthetic regenerative procedures. It helps physicians and practice managers establish objective protocols for patient selection, risk stratification, and informed consent. By operationalizing candidacy assessments, practices improve treatment predictability and patient safety.
The checklist
- Verify complete medical and dermatologic intake forms prior to consultation.
- Document patient Fitzpatrick skin phototype and current tanning/sun exposure habits.
- Identify history of keloid formation, hypertrophic scarring, or abnormal wound healing.
- Screen for active viral, bacterial, or fungal skin lesions in the planned target area.
- Assess recent usage of systemic retinoids, blood thinners, or immunosuppressive therapies.
- Screen for history of facial HSV and initiate antiviral prophylaxis protocols when indicated.
- Capture standardized high-resolution baseline photography under fixed lighting and angles.
- Confirm patient understands realistic physiological timelines and necessary treatment counts.
- Provide written pre-procedure preparation guidelines to the patient at intake.
- Ensure final clinical sign-off by the treating licensed provider prior to procedure scheduling.
Clinical Intake & History Baseline
Establishing a rigorous baseline clinical intake is critical prior to introducing regenerative or minimally invasive aesthetic procedures. Staff should document comprehensive cutaneous history, active systemic conditions, previous aesthetic interventions, and current medication profiles.
Clinicians evaluating dermatology specialties should pay particular attention to historical healing responses, tendencies toward hyperpigmentation or keloid formation, and recent use of topical or systemic agents that alter epidermal barrier integrity.
Absolute vs. Relative Contraindications
A standardized screening framework categorizes patient risk factors into absolute and relative contraindications to prevent avoidable adverse events and non-responder outcomes.
- Absolute Contraindications: Active local cutaneous infection (bacterial, fungal, or viral), active malignancy in the target region, uncontrolled systemic autoimmune flares, or active dermatitis/psoriasis in the treatment area.
- Relative Contraindications: History of Herpes Simplex Virus (HSV) in facial regions (requiring antiviral prophylaxis), recent oral isotretinoin use, current anticoagulant therapy, and Fitzpatrick phototypes IV-VI requiring pre-conditioning parameters.
Indication Mapping for Biologic & Device Modalities
Patient candidacy depends on matching the specific tissue deficit or cosmetic goal with the appropriate therapeutic delivery system. Evaluating skin laxity, photoaging, scar tissue remodeling, or post-procedure recovery dictates whether topically applied regenerative biologics or energy-based clinical devices are indicated.
Standardizing the diagnostic criteria for each treatment category ensures that patient expectations align with the biological mechanism of action of the chosen modality.
Expectation Management & Informed Consent Protocols
Establishing objective parameters for treatment outcomes protects both the practice and the patient. Clinical consent workflows must clearly detail expected downtime, prospective treatment session series, and realistic physiological timelines for skin recovery.
Implementation of high-resolution, standardized baseline photography under identical lighting and positioning is mandatory to provide an objective baseline for subsequent progress evaluations.
Questions practices ask
- How do systemic medications impact patient candidacy for regenerative dermatology procedures?
- Systemic medications such as anticoagulants, oral corticosteroids, or recent systemic retinoids can alter skin barrier restoration and increase risks of hematoma or scarring. Clinicians should evaluate medication timelines and coordinate management before initiating invasive or barrier-disrupting procedures. Standardized intake protocols ensure these drug profiles are highlighted prior to treatment day.
- What screening steps should practices take for high Fitzpatrick phototypes?
- Patients with Fitzpatrick phototypes IV through VI carry a higher risk for post-inflammatory hyperpigmentation (PIH). Screening protocols for these patients should evaluate prior responses to light, heat, or micro-injury and establish pre-conditioning topical regimens or conservative device settings when necessary.
- When should a practice decline or delay a procedure for a potential candidate?
- Procedures should be deferred immediately if active localized skin infections, open wounds, or acute inflammatory flares are present. Additionally, candidates exhibiting unrealistic expectations regarding treatment outcomes or non-compliance with pre-procedure care should be counseled and delayed until criteria are met.
- Who within the practice should perform the initial patient candidacy screening?
- While trained clinical staff or practice managers can administer the preliminary health history questionnaire and intake documentation, final clinical candidacy determination and treatment authorization must remain the responsibility of the licensed treating clinician.
Contact our team to request a clinical consultation on implementing standardized patient candidacy protocols for your dermatology practice. Request a consultation or browse more practice toolkits.
Talk to a regenerative supply specialist
Tell us the service line you are building and we will map the biologics, devices, and supplies that fit your protocol and margins.
- Licensed Texas distributor since 2016
- Protocol, training, and workflow support
- Straight answers on cost per treatment
Most practices hear back the same business day.
Bring regenerative medicine into your practice.
Talk with our team about biologics, devices, or an AI-powered peptide protocol tailored to your patients.